A Look at DARZALEX® (daratumumab) Treatment Regimen in Newly Diagnosed Multiple Myeloma Patients Who are Transplant Eligible
DARZALEX® is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma.
All articles by Stephen Cho
The Vital Role Genetic Testing Plays in Bladder Cancer Treatments
Recent research suggests cancer patients who have undergone genetic testing for inherited or acquired mutations were more likely to have prolonged overall survival than patients who did not,
Daratumumab Maintenance Therapy Improves Depth of Response and Results in Durable PFS
With Robert Rifkin, MD, FACP
Dose Optimization of Duvelisib in Patients With R/R Peripheral T-Cell Lymphoma
With Steven M. Horwitz, MD
-
Loading...
-
Loading...
Next post in Hematologic Cancers
